Memory Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Memory Pharmaceuticals
Starting stock price: $2.69
Ending stock price: $0.56
Percent Change: -79.18%
Details: In March of 2007, Memory's stock took a hit after researchers announced that its lead drug--MEM 1003--failed to achieve any of its endpoints in a mid-stage study for mania in bipolar patients. Results of the same drug as a therapy for Alzheimer's were no better, and the company's stock suffered another major hit in October when MEM 1003 fell short in demonstrating a statistically significant response for improved symptoms after 12 weeks.
More News:
Memory's Alzheimer's drug aces Phase II. Report
Memory's Alzheimer's drug flunks Phase II. Report
Memory shares plunge as lead drug fails trial. Report
More stories about Memory Pharmaceuticals
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
